HIV infections, HIV-Associated Lipodystrophy Syndrome
Conditions
Interventions
Placebo Group: 19 participants received placebo capsules containing neutral talc once a day for 90 days. Before and after placebo intervention, all participants were submitted to clinical, nutritional
Dietary supplement
Sponsors
Faculdade de Medicina de Ribeirão Preto USP
Faculdade de Medicina de Ribeirão Preto USP
Eligibility
Sex/Gender
Male
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Men; adult; HIV-positive; ART for at least 6 months; with lipodystrophy.
Exclusion criteria
Exclusion criteria: Previous thyroidectomy or thyroid dysfunction; in use of glucocorticoids at the last year; with signs or symptoms of opportunistic infections; hepatic dysfunction; renal dysfunction; using insulin or hypoglycemic; taking vitamin and or mineral supplementation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Increased insulin sensitivity observed by HOMA-IR (Homeostatic Model Assessment - Insulin Resistance) from the observation of a variation of at least 5% in the pre and post intervention measurements.;Improvement of the lipid profile verified by total cholesterol, HDL-cholesterol, LDL-cholesterol and triglycerides of a variation of at least 5% in the pre and post intervention measurements. | — |
Secondary
| Measure | Time frame |
|---|---|
| Reduction of pro-inflammatory biomarkers verified by TNF, IL-6, IL-8 and MCP-1; reduction of oxidative stress verified by malondiladeido (MDA) and glutathione (GSH) and body composition verified by reduction of the body fat percentage of a variation of at least 5% in the pre and post intervention measurements. | — |
Countries
Brazil
Contacts
Public ContactAnderson Navarro
Faculdade de Medicina de Ribeirão Preto USP
Outcome results
None listed